News

MedPage Today on MSN5d
Targeted Treatment Improves Disability in Guillain-Barre Syndrome
The primary endpoint, outcome on the GBS Disability Score (GBS-DS) at 8 weeks, showed 29% of patients treated with ...
Fierce Pharma8d
Annexon rolls out Guillain-Barré awareness campaign for HCPs amid promising results for targeted therapy
As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another ...
Quotidianosanità.it3y
Vaccini Covid. Sindrome di Guillain-Barré aggiunta come effetto indesiderato molto raro per il vaccino Johnson & Johnson
23 LUG - La sindrome di Guillain-Barré (GBS) sarà aggiunta alla lista degli effetti indesiderati del vaccino Janssen (Johnson & Johnson) Covid-19 con frequenza molto rara e sarà inserita un ...
BioSpace8d
Annexon Touts ‘Rapid’ and ‘Durable’ Improvements for Targeted Guillain-Barré Therapy
To beef up its case for tanruprubart, Annexon also announced on Wednesday that a real-world study of the drug likewise showed a “rapid increase in muscle strength” versus current standards of care in ...